Search

Your search keyword '"Gonzalez-Ceron, Lilia"' showing total 23 results
Start Over "Gonzalez-Ceron, Lilia"
23 results on '"Gonzalez-Ceron, Lilia"'

2. Primaquine for uncomplicated Plasmodium vivax malaria in children younger than 15 years: a systematic review and individual patient data meta-analysis

Author

Adhikari, Bipin, Alam, Mohammad Shafiul, Anstey, Nicholas M, Assefa, Ashenafi, Baird, J Kevin, Boyd, Sarah C, Chau, Nguyen H, Day, Nicholas PJ, Degaga, Tamiru Shibiru, Dondorp, Arjen M, Erhart, Annette, Ferreira, Marcelo U, Ghimire, Prakash, Khan, Wasif A, Ley, Benedikt, Mekuria, Asrat H, Mueller, Ivo, Naadim, Mohammad N, Nosten, Francois, Price, David J, Pukrittayakamee, Sasithon, Rowland, Mark, Sattabongkot, Jetsumon, SuarezKurtz, Guilherme, Sutanto, Inge, von Seidlein, Lorenz, William, Timothy, Woodrow, Charles J, Woyessa, Adugna, Commons, Robert J, Rajasekhar, Megha, Allen, Elizabeth N, Yilma, Daniel, Chotsiri, Palang, Abreha, Tesfay, Adam, Ishag, Awab, Ghulam Rahim, Barber, Bridget E, Brasil, Larissa W, Chu, Cindy S, Cui, Liwang, Edler, Peta, Gomes, Margarete do Socorro M, Gonzalez‑Ceron, Lilia, Grigg, Matthew J, Hamid, Muzamil Mahdi Abdel, Hwang, Jimee, Karunajeewa, Harin, Lacerda, Marcus V G, Ladeia-Andrade, Simone, Leslie, Toby, Longley, Rhea J, Monteiro, Wuelton Marcelo, Pasaribu, Ayodhia Pitaloka, Poespoprodjo, Jeanne Rini, Richmond, Caitlin L, Rijal, Komal Raj, Taylor, Walter R J, Thanh, Pham Vinh, Thriemer, Kamala, Vieira, José Luiz F, White, Nicholas J, Zuluaga-Idarraga, Lina M, Workman, Lesley J, Tarning, Joel, Stepniewska, Kasia, Guerin, Philippe J, Simpson, Julie A, Barnes, Karen I, and Price, Ric N

Published
2024
Full Text
View/download PDF

3. Effect of adherence to primaquine on the risk of Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis

Author

Mehdipour, Parinaz, Rajasekhar, Megha, Dini, Saber, Zaloumis, Sophie, Abreha, Tesfay, Adam, Ishag, Awab, Ghulam Rahim, Baird, J. Kevin, Brasil, Larissa W., Chu, Cindy S., Cui, Liwang, Daher, André, do Socorro M Gomes, Margarete, Gonzalez‑Ceron, Lilia, Hwang, Jimee, Karunajeewa, Harin, Lacerda, Marcus V. G., Ladeia-Andrade, Simone, Leslie, Toby, Ley, Benedikt, Lidia, Kartini, Llanos-Cuentas, Alejandro, Longley, Rhea J., Monteiro, Wuelton Marcelo, Pereira, Dhelio B., Rijal, Komal Raj, Saravu, Kavitha, Sutanto, Inge, Taylor, Walter R. J., Thanh, Pham Vinh, Thriemer, Kamala, Vieira, José Luiz F., White, Nicholas J., Zuluaga-Idarraga, Lina M., Guerin, Philippe J., Price, Ric N., Simpson, Julie A., and Commons, Robert J.

Published
2023
Full Text
View/download PDF

4. Effect of primaquine dose on the risk of recurrence in patients with uncomplicated Plasmodium vivax: a systematic review and individual patient data meta-analysis

Author

Adhikari, Bipin, Anstey, Nicholas M, Assefa, Ashenafi, Boyd, Sarah C, Chau, Nguyen Hoang, Day, Nicholas PJ, Degaga, Tamiru Shibiru, Dondorp, Arjen M, Erhart, Annette, Ferreira, Marcelo Urbano, Ghimire, Prakash, Green, Justin A, Koh, Gavin CKW, Mekuria, Asrat Hailu, Mueller, Ivo, Naadim, Mohammad Nader, Nelwan, Erni J, Nosten, Francois, Price, David J, Sattabongkot, Jetsumon, Stepniewska, Kasia, von Seidlein, Lorenz, William, Timothy, Woodrow, Charles J, Woyessa, Adugna, Commons, Robert J, Rajasekhar, Megha, Edler, Peta, Abreha, Tesfay, Awab, Ghulam R, Baird, J Kevin, Barber, Bridget E, Chu, Cindy S, Cui, Liwang, Daher, André, Gonzalez-Ceron, Lilia, Grigg, Matthew J, Hwang, Jimee, Karunajeewa, Harin, Lacerda, Marcus V G, Ladeia-Andrade, Simone, Lidia, Kartini, Llanos-Cuentas, Alejandro, Longley, Rhea J, Pereira, Dhelio B, Pasaribu, Ayodhia P, Pukrittayakamee, Sasithon, Rijal, Komal R, Sutanto, Inge, Taylor, Walter R J, Thanh, Pham V, Thriemer, Kamala, Vieira, José Luiz F, Watson, James A, Zuluaga-Idarraga, Lina M, White, Nicholas J, Guerin, Philippe J, Simpson, Julie A, and Price, Ric N

Published
2024
Full Text
View/download PDF

5. Primaquine for uncomplicated Plasmodium vivaxmalaria in children younger than 15 years: a systematic review and individual patient data meta-analysis

Author

Commons, Robert J, Rajasekhar, Megha, Allen, Elizabeth N, Yilma, Daniel, Chotsiri, Palang, Abreha, Tesfay, Adam, Ishag, Awab, Ghulam Rahim, Barber, Bridget E, Brasil, Larissa W, Chu, Cindy S, Cui, Liwang, Edler, Peta, Gomes, Margarete do Socorro M, Gonzalez‑Ceron, Lilia, Grigg, Matthew J, Hamid, Muzamil Mahdi Abdel, Hwang, Jimee, Karunajeewa, Harin, Lacerda, Marcus V G, Ladeia-Andrade, Simone, Leslie, Toby, Longley, Rhea J, Monteiro, Wuelton Marcelo, Pasaribu, Ayodhia Pitaloka, Poespoprodjo, Jeanne Rini, Richmond, Caitlin L, Rijal, Komal Raj, Taylor, Walter R J, Thanh, Pham Vinh, Thriemer, Kamala, Vieira, José Luiz F, White, Nicholas J, Zuluaga-Idarraga, Lina M, Workman, Lesley J, Tarning, Joel, Stepniewska, Kasia, Guerin, Philippe J, Simpson, Julie A, Barnes, Karen I, Price, Ric N, Adhikari, Bipin, Alam, Mohammad Shafiul, Anstey, Nicholas M, Assefa, Ashenafi, Baird, J Kevin, Boyd, Sarah C, Chau, Nguyen H, Day, Nicholas PJ, Degaga, Tamiru Shibiru, Dondorp, Arjen M, Erhart, Annette, Ferreira, Marcelo U, Ghimire, Prakash, Khan, Wasif A, Ley, Benedikt, Mekuria, Asrat H, Mueller, Ivo, Naadim, Mohammad N, Nosten, Francois, Price, David J, Pukrittayakamee, Sasithon, Rowland, Mark, Sattabongkot, Jetsumon, SuarezKurtz, Guilherme, Sutanto, Inge, von Seidlein, Lorenz, William, Timothy, Woodrow, Charles J, and Woyessa, Adugna

Abstract

Primaquine, the only widely available treatment to prevent relapsing Plasmodium vivaxmalaria, is produced as 15 mg tablets, and new paediatric formulations are being developed. To inform the optimal primaquine dosing regimen for children, we aimed to determine the efficacy and safety of different primaquine dose strategies in children younger than 15 years.

Published
2024
Full Text
View/download PDF

6. The effect of chloroquine dose and primaquine on Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient pooled meta-analysis

Author

Commons, Robert J, Simpson, Julie A, Thriemer, Kamala, Humphreys, Georgina S, Abreha, Tesfay, Alemu, Sisay G, Añez, Arletta, Anstey, Nicholas M, Awab, Ghulam R, Baird, J Kevin, Barber, Bridget E, Borghini-Fuhrer, Isabelle, Chu, Cindy S, D'Alessandro, Umberto, Dahal, Prabin, Daher, André, de Vries, Peter J, Erhart, Annette, Gomes, Margarete S M, Gonzalez-Ceron, Lilia, Grigg, Matthew J, Heidari, Aliehsan, Hwang, Jimee, Kager, Piet A, Ketema, Tsige, Khan, Wasif A, Lacerda, Marcus V G, Leslie, Toby, Ley, Benedikt, Lidia, Kartini, Monteiro, Wuelton M, Nosten, Francois, Pereira, Dhelio B, Phan, Giao T, Phyo, Aung P, Rowland, Mark, Saravu, Kavitha, Sibley, Carol H, Siqueira, André M, Stepniewska, Kasia, Sutanto, Inge, Taylor, Walter R J, Thwaites, Guy, Tran, Binh Q, Tran, Hien T, Valecha, Neena, Vieira, José Luiz F, Wangchuk, Sonam, William, Timothy, Woodrow, Charles J, Zuluaga-Idarraga, Lina, Guerin, Philippe J, White, Nicholas J, and Price, Ric N

Published
2018
Full Text
View/download PDF

8. Effect of Primaquine Dose on the Risk of Recurrence in Patients with Uncomplicated  Plasmodium Vivax: A Systematic Review and Individual Patient Data Meta-Analysis

Author

Commons, Robert J., primary, Rajasekhar, Megha, additional, Edler, Peta, additional, Abreha, Tesfay, additional, Awab, Ghulam Rahim, additional, Baird, J. Kevin, additional, Barber, Bridget, additional, Chu, Cindy S., additional, Cui, Liwang, additional, Daher, Andre, additional, Gonzalez-Ceron, Lilia, additional, Grigg, Matthew J., additional, Hwang, Jimee, additional, Karunajeewa, Harin, additional, Lacerda, Marcus, additional, Ladeia-Andrade, Simone, additional, Lidia, Kartini, additional, Llanos-Cuentas, Alejandro, additional, Longley, Rhea J., additional, Pereira, Dhelio B., additional, Pasaribu, Ayodhia Pitaloka, additional, Pukrittayakamee, Sasithon, additional, Rijal, Komal Raj, additional, Sutanto, Inge, additional, Taylor, Walter, additional, Thanh, Pham Vinh, additional, Thriemer, Kamala, additional, Vieira, Jose Luis F., additional, Watson, James A., additional, Zuluaga-Idarraga, Lina M., additional, White, Nicholas J., additional, Guerin, Philippe, additional, Simpson, Julie A., additional, Price, Ric N., additional, and Study Group, WorldWide Antimalarial Resistance Network (WWARN), additional

Published
2023
Full Text
View/download PDF

11. MOESM4 of Effectiveness of combined chloroquine and primaquine treatment in 14Â days versus intermittent single dose regimen, in an open, non-randomized, clinical trial, to eliminate Plasmodium vivax in southern Mexico

Author

Gonzalez-Ceron, Lilia, Rodriguez, Mario, Sandoval, Marco, Santillan, Frida, Galindo-Virgen, Sonia, Betanzos, Angel, Rosales, Angel, and Palomeque, Olga

Subjects
parasitic diseases
Abstract

Additional file 4. Plasmodium vivax genotypes from two groups of patients treated with combined chloroquine and primaquine by the intermittent single dose (ISD) and 14-day (T14) regimens.

Published
2015
Full Text
View/download PDF

13. Effectiveness of combined chloroquine and primaquine treatment in 14 days versus intermittent single dose regimen, in an open, non-randomized, clinical trial, to eliminate Plasmodium vivax in southern Mexico

Author

Gonzalez-Ceron, Lilia, primary, Rodriguez, Mario H., additional, Sandoval, Marco A., additional, Santillan, Frida, additional, Galindo-Virgen, Sonia, additional, Betanzos, Angel F., additional, Rosales, Angel F., additional, and Palomeque, Olga L., additional

Published
2015
Full Text
View/download PDF

14. Differential Susceptibilities of Anopheles albimanus and Anopheles pseudopunctipennis to Infections with Coindigenous Plasmodium vivax Variants VK210 and VK247 in Southern Mexico

Author

Gonzalez-Ceron, Lilia, Rodriguez, Mario H., Nettel, Jose C., Villarreal, Cuauhtemoc, Kain, Kevin C., and Hernandez, Juan E.

Subjects
Protozoan Proteins, Antigens, Protozoan, Antigenic Variation, Immunity, Innate, Insect Vectors, Logistic Models, parasitic diseases, Anopheles, Malaria, Vivax, Animals, Humans, Disease Susceptibility, Fungal and Parasitic Infections, Plasmodium vivax, Mexico
Abstract

The susceptibilities to coindigenous Plasmodium vivax of colonized Anopheles albimanus and Anopheles pseudopunctipennis from southern Mexico were investigated by simultaneous feeding with infected blood obtained from patients. The genes encoding circumsporozoite protein variant types (VK210 and VK247) in blood samples were determined by PCR and oligonucleotide probe hybridization. A. albimanus was more susceptible to VK210, and A. pseudopunctipennis was more susceptible to VK247.

Published
1999

22. Differential Susceptibilities of Anopheles albimanusand Anopheles pseudopunctipennisto Infections with Coindigenous Plasmodium vivaxVariants VK210 and VK247 in Southern Mexico

Author

Gonzalez-Ceron, Lilia, Rodriguez, Mario H., Nettel, Jose C., Villarreal, Cuauhtemoc, Kain, Kevin C., and Hernandez, Juan E.

Abstract

ABSTRACTThe susceptibilities to coindigenous Plasmodium vivaxof colonized Anopheles albimanusand Anopheles pseudopunctipennisfrom southern Mexico were investigated by simultaneous feeding with infected blood obtained from patients. The genes encoding circumsporozoite protein variant types (VK210 and VK247) in blood samples were determined by PCR and oligonucleotide probe hybridization. A. albimanuswas more susceptible to VK210, and A. pseudopunctipenniswas more susceptible to VK247.

Published
1999
Full Text
View/download PDF

23. Effect of primaquine dose on the risk of recurrence in patients with uncomplicated Plasmodium vivax: a systematic review and individual patient data meta-analysis.

Author

Commons, Robert J, Rajasekhar, Megha, Edler, Peta, Abreha, Tesfay, Awab, Ghulam R, Baird, J Kevin, Barber, Bridget E, Chu, Cindy S, Cui, Liwang, Daher, André, Gonzalez-Ceron, Lilia, Grigg, Matthew J, Hwang, Jimee, Karunajeewa, Harin, Lacerda, Marcus V G, Ladeia-Andrade, Simone, Lidia, Kartini, Llanos-Cuentas, Alejandro, Longley, Rhea J, and Pereira, Dhelio B

Subjects
*PLASMODIUM vivax, *PRIMAQUINE, *DISEASE relapse, *POISSON regression, *MEDICAL research
Abstract

Primaquine is used to eliminate Plasmodium vivax hypnozoites, but its optimal dosing regimen remains unclear. We undertook a systematic review and individual patient data meta-analysis to investigate the efficacy and tolerability of different primaquine dosing regimens to prevent P vivax recurrence. For this systematic review and individual patient data meta-analysis, we searched MEDLINE, Web of Science, Embase, and Cochrane Central for prospective clinical studies of uncomplicated P vivax from endemic countries published between Jan 1, 2000, and June 8, 2023. We included studies if they had active follow-up of at least 28 days, and if they included a treatment group with daily primaquine given over multiple days, where primaquine was commenced within 7 days of schizontocidal treatment and was given alone or coadministered with chloroquine or one of four artemisinin-based combination therapies (ie, artemether–lumefantrine, artesunate–mefloquine, artesunate–amodiaquine, or dihydroartemisinin–piperaquine). We excluded studies if they were on prevention, prophylaxis, or patients with severe malaria, or if data were extracted retrospectively from medical records outside of a planned trial. For the meta-analysis, we contacted the investigators of eligible trials to request individual patient data and we then pooled data that were made available by Aug 23, 2021. We assessed the effects of total dose and duration of primaquine regimens on the rate of first P vivax recurrence between day 7 and day 180 by Cox's proportional hazards regression (efficacy analysis). The effect of primaquine daily dose on gastrointestinal symptoms on days 5–7 was assessed by modified Poisson regression (tolerability analysis). The study was registered with PROSPERO, CRD42019154470. Of 226 identified studies, 23 studies with patient-level data from 6879 patients from 16 countries were included in the efficacy analysis. At day 180, the risk of recurrence was 51·0% (95% CI 48·2–53·9) in 1470 patients treated without primaquine, 19·3% (16·9–21·9) in 2569 patients treated with a low total dose of primaquine (approximately 3·5 mg/kg), and 8·1% (7·0–9·4) in 2811 patients treated with a high total dose of primaquine (approximately 7 mg/kg), regardless of primaquine treatment duration. Compared with treatment without primaquine, the rate of P vivax recurrence was lower after treatment with low-dose primaquine (adjusted hazard ratio 0·21, 95% CI 0·17–0·27; p<0·0001) and high-dose primaquine (0·10, 0·08–0·12; p<0·0001). High-dose primaquine had greater efficacy than low-dose primaquine in regions with high and low relapse periodicity (ie, the time from initial infection to vivax relapse). 16 studies with patient-level data from 5609 patients from ten countries were included in the tolerability analysis. Gastrointestinal symptoms on days 5–7 were reported by 4·0% (95% CI 0·0–8·7) of 893 patients treated without primaquine, 6·2% (0·5–12·0) of 737 patients treated with a low daily dose of primaquine (approximately 0·25 mg/kg per day), 5·9% (1·8–10·1) of 1123 patients treated with an intermediate daily dose (approximately 0·5 mg/kg per day) and 10·9% (5·7–16·1) of 1178 patients treated with a high daily dose (approximately 1 mg/kg per day). 20 of 23 studies included in the efficacy analysis and 15 of 16 in the tolerability analysis had a low or unclear risk of bias. Increasing the total dose of primaquine from 3·5 mg/kg to 7 mg/kg can reduce P vivax recurrences by more than 50% in most endemic regions, with a small associated increase in gastrointestinal symptoms. Australian National Health and Medical Research Council, Bill & Melinda Gates Foundation, and Medicines for Malaria Venture. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results